For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
|
| Basic information |
| Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
| Chen,Chi-Chuan |
Her, Jeng-Horng |
Her, Jeng-Horng |
02-26532886 |
11F-2，No508，Sec7，Zhongxao E RdTaipei, Taiwan |
2023/07/14 |
| Industrycategory |
Key businesses |
| Biotechnology and Medical Care |
Over the last 20 years, the growth of biotherapeutic antibodies, has had a dramatic impact on many areas of medicine, including infectious, immune-mediated, and respiratory diseases, as well as hematology and oncology. APBio is currently developing fully-human，mono- and bi-specific antibodies with novel mechanisms of action to fulfill unmet medical needs.
Combining our integrated protein engineering and antibody technology, we have produced a portfolio of biotherapeutic leads & bi-specific antibodies to treat serious medical conditions with a primary clinical focus on oncology. With mechanism-based drug design focusing on disease-specific targets, we are aiming to provide patients with medicines that are safe, efficacious and cost-effective. We believe that the biotherapeutics developed this way will offer important clinical and economic advantages, making these protein drugs better choices for the patients. |
| Financial data |
| Cash flows statement
| Item
|
|
|
| Amount(NTD, in thousands) |
| Cash flows from operating activities |
|
|
| Cash flows from investing activities |
|
|
| Cash flows from financing activities |
|
|
Consolidated/Individual
balance sheet
|
Current assets |
|
|
| Non-current assets |
|
|
| Total assets |
|
|
| Current liabilities |
|
|
| Non-current liabilities |
|
|
| Total liabilities |
|
|
| Share capital |
|
|
| Capital surplus |
|
|
| Retained earnings |
|
|
| Other equity interest |
|
|
| Treasury shares |
|
|
| Total equity attributable to owners of parent |
|
|
| Non-controlling interests |
|
|
| Total equity |
|
|
| Book Value per share(NT$) |
|
|
Consolidated/Individual
profit and loss
statement |
Operating revenue |
|
|
| Operating costs |
|
|
| Gross profit from operations |
|
|
| Operating expenses |
|
|
| Net other income (expenses) |
|
|
| Net operating income |
|
|
| Non-operating income and expenses |
|
|
| Profit before tax |
|
|
| Tax expense |
|
|
| Profit from continuing operations |
|
|
| Profit from discontinued operations |
|
|
| Profit |
|
|
| Other comprehensive income |
|
|
| Comprehensive income |
|
|
| Basic earnings per share |
|
|
 Auditor's report on latest financial statements： auditor's report：
|
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|
